Adenosine analogues for the treatment of the insulin resistance syndrome and diabetes
Details for Australian Patent Application No. 2002342317 (hide)
International Classifications
Event Publications
27 February 2003 Complete Application Filed
Priority application(s): 01111651.4 14.05.01 EP
1 May 2003 Application Open to Public Inspection
Published as AU-A-2002342317
5 January 2006 Change of Name(s) of Applicant(s), Section 104
Aventis Pharma Deutschland GmbH The name of the applicant has been changed to Sanofi-Aventis Deutschland GmbH 2003
3 January 2008 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired
This application lapsed under section 142(2)(d). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.
Legal
The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.
Next and Previous Patents/Applications
2002342318-Novel 1,2,4-thiadiazole derivatives as melanocortin receptor modulators
IP Reporting Samples
Customised IP Reporting
IP Insider for IP Professionals
IP Monitor Professional
- Editable Word format reports
- For IP Professionals
- Multiuser